Psilocybin-assisted therapy is being investigated for post-traumatic stress disorder, with early studies reporting substantial reductions in symptoms in some participants. The evidence remains preliminary: the main published psilocybin PTSD studies are small and uncontrolled. Clinical improvement is possible, but the contribution of the drug, psychological support and other influences has not yet been established with confidence.
Improvement after treatment is not the same as proof that psilocybin caused it. Evidence for MDMA-assisted therapy is also separate from evidence for psilocybin: the drugs, treatment programmes and supporting trials differ.
On this page
- What treatment for PTSD needs to change
- Why psilocybin might be relevant
- The first multicentre psilocybin PTSD study
- A pilot in veterans and the role of preparation
- Why MDMA findings cannot be transferred to psilocybin
- Memory, suggestion and therapeutic boundaries
- Risk assessment and care after the session
- Established treatment and the current clinical position
What treatment for PTSD needs to change
PTSD can involve intrusive memories or nightmares, avoidance of reminders, persistent threat responses, disturbed sleep and changes in mood or beliefs. Symptoms can restrict relationships, employment and ordinary activities long after the precipitating event. Exposure to trauma does not inevitably lead to PTSD, and distress after trauma requires assessment in its clinical and social context.1
Treatment aims to reduce persistent symptoms and restore the capacity to live more freely. Forgetting the event is not a necessary marker of recovery. Neither is producing an emotionally overwhelming account of it. Someone may remember what happened while becoming less dominated by avoidance, shame or a continuing sense of danger.
Psychological change also takes place within present circumstances. Continuing abuse, insecure housing or other ongoing threats cannot be resolved solely by changing a person’s response to memories. Clinical care needs to distinguish a trauma reminder from an actual current danger and include practical protection and support when required.2
Why psilocybin might be relevant
Psilocybin’s active metabolite, psilocin, affects serotonin receptors and can produce marked changes in perception, emotion and the sense of self. In a therapeutic setting, investigators hope that these effects might make entrenched patterns of avoidance or interpretation more open to change. These are proposed clinical mechanisms, rather than established explanations of recovery from PTSD.34
The same alterations can also make a person frightened, confused or unusually vulnerable to suggestion. Preparation, consent and the conduct of the therapeutic team therefore matter independently of any potential drug effect. An intense experience should not be treated as evidence that traumatic memories have been accurately recovered or that successful treatment has occurred.56
The first multicentre psilocybin PTSD study
A nonrandomised open-label study of 22 adults assessed a single supported psilocybin session. Its primary purpose was safety and tolerability; symptom outcomes were secondary. Mean scores on the Clinician-Administered PTSD Scale for DSM-5, or CAPS-5, fell by approximately 30 points at four weeks, with a similar average reduction at twelve weeks. This is a substantial within-group change, but there was no placebo or active-treatment comparison.7
The participants were selected. People with complex PTSD were excluded, as were those whose primary PTSD arose from childhood abuse. The results therefore cannot be assumed to describe treatment of complex developmental trauma. The trial also excluded significant current suicide risk, which limits conclusions about people requiring more acute support.7
No serious treatment-emergent adverse events or withdrawals were reported. There were nevertheless severe transient events, and two participants experienced episodes of suicidal ideation during follow-up; both had a history of suicidality. One episode occurred on the dosing day and another several weeks later. “Severe” describes intensity, whereas “serious” is a separate clinical-trial classification. The absence of serious events should not be paraphrased as an absence of clinically important difficulties.7
The symptom reductions make further controlled investigation reasonable. They do not establish the likelihood of benefit in routine care, the contribution of supportive contact, or whether additional sessions would improve outcomes. A carefully selected group receiving close follow-up is a specific clinical setting, not a sample of everyone living with PTSD.
A pilot in veterans and the role of preparation
A 2026 open-label study reported outcomes for twelve veterans with severe, treatment-resistant PTSD who completed two supported psilocybin sessions. At one month after the second session, mean CAPS-5 scores had fallen by 27.5 points; nine participants met the study’s response and remission criteria. Symptoms had already improved significantly during preparation, before psilocybin was given. There were no serious adverse events, but the sample was medically selected and follow-up was short.8
Remission at an assessment is not a guarantee of permanent recovery. This pilot also cannot distinguish drug effects from the considerable psychological support provided. Improvement before drug administration is particularly relevant when interpreting the treatment package: preparation may contribute to change, and its contribution should not automatically be attributed to psilocybin.
| Finding | Reasonable interpretation | Unjustified extension |
|---|---|---|
| PTSD scores fall after treatment | Participants improved during the treatment period. | Psilocybin alone caused the improvement. |
| Some participants meet remission criteria | Symptoms are below the study threshold at that assessment. | The trauma has been permanently cured. |
| A small selected group has no serious adverse events | No such events were observed in that group. | The treatment is safe for all trauma survivors. |
| Preparation precedes symptom improvement | Non-drug elements may contribute to the outcome. | Preparation and continuing care are optional. |
Why MDMA findings cannot be transferred to psilocybin
MDMA is pharmacologically different from a classic serotonergic psychedelic such as psilocybin. Its effects involve monoamine release, and the therapeutic programmes studied with it are distinct. Combining the two under a broad psychedelic-therapy label can obscure clinically important differences in efficacy, harms and treatment delivery.4
A 2023 phase 3 trial randomised 104 people with moderate to severe PTSD to MDMA or placebo, each with a manualised therapy programme. Mean CAPS-5 reductions were greater with MDMA-assisted therapy, approximately 23.7 versus 14.8 points. Unlike the small psilocybin pilots, this provides a randomised comparison. Difficulty maintaining blinding and the intensive treatment context still affect interpretation and generalisability.9
Those findings do not show that psilocybin has the same effect. Nor should clinical trial results be confused with authorisation for routine treatment. The US National Center for PTSD’s current patient information states that MDMA-assisted therapy is not FDA approved. Regulatory status, local access and the evidence for an individual drug are separate questions.10
Memory, suggestion and therapeutic boundaries
A vivid image or a strong feeling of certainty during a psychedelic session is an experience to discuss, not independent confirmation of a historical event. The clinical task is to understand its emotional and practical significance without encouraging unsupported factual conclusions. Leading questions, demands to identify hidden abuse or confident interpretations imposed by a therapist can be harmful.611
Consent should address the expected alteration of consciousness, foreseeable discomfort, the limits of the treatment and the person’s preferences about interaction. Boundaries around touch, privacy and disclosure need to be clear before a session. A person should not be required to accept a therapist’s spiritual, sexual or autobiographical interpretation to remain eligible for care.5
Fear, dissociation or a worsening sense of safety require a clinical response. They should not be automatically interpreted as necessary breakthroughs. Persistent deterioration, new suicidal thinking or inability to function needs prompt assessment and an appropriate care plan.
Risk assessment and care after the session
Assessment extends beyond a PTSD diagnosis. It includes current symptoms, dissociation, suicide risk, psychosis or mania history, physical health, substance use, medicines and available support. Eligibility rules vary between protocols, and evidence from screened trial participants cannot establish safety for someone excluded from those trials. Trauma severity alone does not determine whether a psychedelic intervention is appropriate.75
Medication decisions require particular care. Stopping a treatment to qualify for a trial may create withdrawal symptoms or destabilisation, while continuing it may raise interaction questions. These are prescribing decisions for the responsible clinical team. A general claim that antidepressants block all therapeutic benefit is not an adequate basis for discontinuation.12
Follow-up should assess sleep, intrusive symptoms, avoidance, functioning and adverse effects over time. It should allow discussion of disappointment and ambivalence as well as improvement. A useful account of treatment includes people who did not benefit, withdrew or became worse; restricting attention to striking positive experiences creates an incomplete picture.
Established treatment and the current clinical position
NICE recommends individual trauma-focused cognitive behavioural treatments for adults with PTSD, including approaches such as cognitive processing therapy, cognitive therapy for PTSD and prolonged exposure. It also recommends EMDR in specified circumstances for non-combat-related trauma. An SSRI such as sertraline or venlafaxine may be considered when an adult prefers medication, with regular review. Choice should reflect clinical assessment, preferences and access to suitably trained care.2
Previous unsuccessful treatment should prompt examination of what was offered, its duration, tolerability and the person’s circumstances. It does not establish that standard care can never help or that a psychedelic session is the inevitable next step. Continuing therapy and practical support remain relevant whether or not someone enters a research study.
Psilocybin for PTSD is a promising but unconfirmed clinical possibility. The early changes in symptoms warrant controlled trials with longer follow-up, broader representation and careful monitoring of harms. Until those questions are resolved, the appropriate conclusion is preliminary evidence of potential benefit within supported research settings, without a reliable estimate of added efficacy or durable recovery.
For prolonged anxiety, dissociation and symptoms that need further assessment, see:
For a separate discussion of the controlled MDMA trials and the differences from psilocybin treatment, see:
References
- National Institute of Mental Health. Traumatic Events and Post-Traumatic Stress Disorder (PTSD). Reviewed December 2024; accessed 11 October 2026.
- National Institute for Health and Care Excellence. Post-traumatic stress disorder (NG116). Recommendations; accessed 11 October 2026.
- Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264–355. doi:10.1124/pr.115.011478.
- US Department of Veterans Affairs, National Center for PTSD. Psychedelic-Assisted Therapy for PTSD. Clinical information; accessed 11 October 2026.
- Johnson MW, Richards WA, Griffiths RR. Human Hallucinogen Research: Guidelines for Safety. J Psychopharmacol. 2008;22:603–620. doi:10.1177/0269881108093587.
- McGovern HT, Grimmer HJ, Doss MK, et al. An Integrated theory of false insights and beliefs under psychedelics. Commun Psychol. 2024;2:69. doi:10.1038/s44271-024-00120-6.
- McGowan NM, Rucker JJ, Yehuda R, et al. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. J Psychopharmacol. 2026;40:139-148. doi:10.1177/02698811251362390.
- Armstrong SB, Levin AW, Sepeda ND, et al. Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial. Commun Med. 2026;6:411. doi:10.1038/s43856-026-01767-4.
- Mitchell JM, Ot'alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473-2480. doi:10.1038/s41591-023-02565-4.
- US Department of Veterans Affairs, National Center for PTSD. MDMA-Assisted Therapy. Patient information; accessed 11 October 2026.
- Kangaslampi S, Wolff M, Doss MK, et al. Questioning the recovery of dissociated traumatic memories under psilocybin: comment on "Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa". J Eat Disord. 2025;13:278. doi:10.1186/s40337-025-01484-8.
- Halman A, et al. Drug–drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. 2024. doi:10.1177/02698811231211219.